Is ruxolitinib phosphate tablets/ruxolitinib a targeted therapy drug?

Ruxolitinib tablets/ruxolitinib(JAKAVI) belongs to the category of targeted therapy drugs. As a selective Janus kinase (JAK) inhibitor, it precisely targets JAK1 and JAK2, two enzymes that play key roles in the cytokine signaling pathway, thereby regulating immune responses and cell proliferation. The core concept of targeted therapy is to precisely intervene on specific molecules or signaling pathways to reduce non-selective damage to normal tissues, and ruxolitinib is one of the representative drugs for this concept.

Target of ruxolitinibThe JAK-STAT pathway has been found to be abnormally activated in many hematopoietic and immune diseases, especially inmyelofibrosis (MF) and polycythemia vera (PV). Abnormalities in this pathway can lead to uncontrolled hematopoietic system, increased levels of inflammatory factors, and ultimately symptoms such as splenomegaly, fatigue and weight loss. Traditional chemotherapy drugs usually have extensive mechanisms of action and may affect rapidly dividing normal cells at the same time. Ruxolitinib can control the disease in a more targeted manner by precisely inhibiting the key JAK1/2 enzyme activity in the disease pathway. This is one of its core advantages that distinguishes it from traditional drugs.

Targeting is also reflected in its treatment strategy. In patients with myelofibrosis, ruxolitinib can significantly reduce the size of the spleen and improve systemic symptoms mainly involving inflammation such as itching, bone pain, and night sweats. In polycythemia vera, it can be used as an alternative to control excessive blood cell proliferation in patients who are intolerant or have poor response to hydroxyurea. This targeted regulation is not achieved by destroying the cells themselves, but by intervening in their signal transduction, regulating the disease microenvironment, and reconstructing the pathological process from a mechanistic perspective. This mechanistic "precision treatment" is the essence of what differentiates targeted drugs from traditional chemotherapy.

Reference materials:https://www.jakavi.com/